Company intelligence / Profile preview

Biolex Therapeutics

Pittsboro, North Carolina, United Statessec.gov ↗

Ownership: Private
Employees: ~90
Development stage: Phase 2

Overview

Biolex Therapeutics was a clinical-stage biopharmaceutical company that developed therapeutic proteins and monoclonal antibodies using its proprietary LEX System. The company successfully completed a Phase 1 clinical trial of BLX-883 (a form of alfa interferon) and was advancing Locteron, a controlled-release interferon alfa for hepatitis C treatment. In May 2012, Biolex sold its LEX System to Synthon before filing for bankruptcy in July 2012.

Therapeutic areas: OncologyInfectious DiseasesHematology
Modalities: Therapeutic proteinsMonoclonal antibodiesRecombinant proteins
Industry: Biotech

Drug pipeline

2 assets

BLX-301

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

CentocorMedarexOctoPlusBayer HealthCareDebiopharm

Beyond the preview

Go deeper on Biolex Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biolex Therapeutics.

Explore the full profile